These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 30339906)
1. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine. Thakkar SG; Warnken ZN; Alzhrani RF; Valdes SA; Aldayel AM; Xu H; Williams RO; Cui Z J Control Release; 2018 Dec; 292():111-118. PubMed ID: 30339906 [TBL] [Abstract][Full Text] [Related]
2. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses. Xu H; Ruwona TB; Thakkar SG; Chen Y; Zeng M; Cui Z Hum Vaccin Immunother; 2017 Nov; 13(11):2688-2694. PubMed ID: 28933668 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration. Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271 [TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures. Thakkar SG; Ruwona TB; Williams RO; Cui Z Hum Vaccin Immunother; 2017 Apr; 13(4):936-946. PubMed ID: 28051903 [TBL] [Abstract][Full Text] [Related]
5. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution. Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896 [TBL] [Abstract][Full Text] [Related]
6. Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01). Hellfritzsch M; Christensen D; Foged C; Scherließ R; Thakur A Int J Pharm; 2023 Dec; 648():123581. PubMed ID: 37931728 [TBL] [Abstract][Full Text] [Related]
7. Curdlan sulfate- Zhang S; Huang S; Lu L; Song X; Li P; Wang F Int J Nanomedicine; 2018; 13():2377-2394. PubMed ID: 29713168 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders. Yu YS; AboulFotouh K; Xu H; Williams G; Suman J; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z Int J Pharm; 2023 Jun; 640():122990. PubMed ID: 37127138 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505 [TBL] [Abstract][Full Text] [Related]
11. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778 [TBL] [Abstract][Full Text] [Related]
12. Thin-Film Freeze-Drying Is a Viable Method to Convert Vaccines Containing Aluminum Salts from Liquid to Dry Powder. Alzhrani RF; Xu H; Moon C; Suggs LJ; Williams RO; Cui Z Methods Mol Biol; 2021; 2183():489-498. PubMed ID: 32959262 [TBL] [Abstract][Full Text] [Related]
13. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice. Scherließ R; Mönckedieck M; Young K; Trows S; Buske S; Hook S Int J Pharm; 2015 Feb; 479(2):408-15. PubMed ID: 25595389 [TBL] [Abstract][Full Text] [Related]
14. Stable dry powder formulation for nasal delivery of anthrax vaccine. Wang SH; Kirwan SM; Abraham SN; Staats HF; Hickey AJ J Pharm Sci; 2012 Jan; 101(1):31-47. PubMed ID: 21905034 [TBL] [Abstract][Full Text] [Related]
15. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824 [TBL] [Abstract][Full Text] [Related]
16. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Huang J; Garmise RJ; Crowder TM; Mar K; Hwang CR; Hickey AJ; Mikszta JA; Sullivan VJ Vaccine; 2004 Dec; 23(6):794-801. PubMed ID: 15542204 [TBL] [Abstract][Full Text] [Related]
17. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Patel GB; Zhou H; Ponce A; Chen W Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279 [TBL] [Abstract][Full Text] [Related]
18. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762 [TBL] [Abstract][Full Text] [Related]
19. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Iyer S; HogenEsch H; Hem SL Vaccine; 2003 Mar; 21(11-12):1219-23. PubMed ID: 12559801 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies. Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]